Medical Library | Shanghai Mental Health and Brain Innovation Series
Shanghai Mental Health Center, affiliated with Shanghai Jiao Tong University, is a major specialist center for geriatric psychiatry, mood disorders, psychopharmacology, cognitive disorders, and brain-based interventions. Its 2025–2026 programs connect early Alzheimer's screening, glymphatic-system research, non-invasive brain–computer interfaces, precision psychiatry, and international evidence evaluation.
This Medical Library review summarizes three representative teams and directions based on the information provided. It also explains how CMCS can help international patients and families prepare for psychiatric, cognitive, and neurotechnology consultations in Shanghai.
1. Geriatric Psychiatry: Early Alzheimer's Screening and Glymphatic-System Intervention
Lead: Professor Li Xia
Focus: Early Alzheimer's disease screening and intervention.
Key 2025–2026 milestones
- “Shu'er” intervention: The program launched what was described as China's first standardized investigator-initiated trial of a cervical–cranial glymphatic drainage-opening procedure.
- “Golden Three Minutes” screening: A cognitive-screening tool was reported to achieve sensitivity and specificity above 85%. It had been used to screen approximately 400,000 older adults across six provinces and municipalities.
The glymphatic system is a network involved in the movement and clearance of fluid and metabolic waste in the brain. Research interest has grown around its relationship with sleep, aging, vascular disease, and neurodegeneration. A procedure intended to improve glymphatic drainage should be understood as an emerging intervention, not as an established cure for Alzheimer's disease.
Before considering an intervention, patients should ask how the diagnosis was confirmed, what the procedure actually involves, what evidence exists in humans, how risks are monitored, and whether the intervention is available only through an investigator-initiated trial. Screening is equally important: a cognitive-screening score is not the same as a diagnosis and may be affected by education, hearing, language, mood, sleep, and acute illness.
For related background, see our Alzheimer's disease and cognitive disorders specialist profile.
Clinical profile: A dual-track program combining scalable cognitive screening with research into glymphatic-system intervention.
2. Mood Disorders: Non-Invasive BCI for Treatment-Resistant Depression and Anxiety
Lead: Professor Zhang Tianhong
Focus: Treatment-resistant depression, anxiety, and emotional disorders in adolescents.
Key 2025–2026 milestones
- Specialist BCI clinic: The first reported non-invasive BCI neuromodulation clinic dedicated to a psychiatric specialty opened on December 10, 2025. By August 2026, it had delivered standardized interventions to hundreds of patient visits.
- Precision closed-loop BCI: A multicenter study of precision closed-loop BCI for treatment-resistant depression was launched.
Non-invasive BCI systems typically use brain signals or neurophysiological markers to guide stimulation or adapt treatment. A closed-loop system attempts to measure the brain's response and adjust stimulation rather than applying the same preset protocol to every patient.
For treatment-resistant depression, BCI or neuromodulation should be considered alongside a full psychiatric assessment. Clinicians need to review diagnosis, bipolar-spectrum symptoms, suicide risk, trauma, sleep, substance use, medication history, psychotherapy, and previous neuromodulation. For adolescents, consent, family involvement, school function, development, and long-term safety are especially important.
Patients should ask whether the intervention is approved, investigational, or part of a research protocol; what outcome is being measured; how many sessions are needed; and what happens if mood symptoms worsen or suicidal thinking appears.
Our Brain–Computer Interface Therapy in Shanghai guide provides broader background on BCI technology.
Clinical profile: A psychiatric program bringing non-invasive and potentially adaptive BCI from research into a structured specialist clinic.
3. Psychopharmacology: Adding Chinese Real-World Evidence to Global Antipsychotic Evaluation
Lead: Professor Li Chunbo, in collaboration with Professor Stefan Leucht of Technical University of Munich
Focus: Schizophrenia, bipolar disorder, and optimization of antipsychotic treatment.
A China–Germany collaboration reported in The Lancet in March 2026 incorporated evidence from Chinese-language databases into the international evaluation of antipsychotic medicines.
This work matters because evidence used in treatment guidelines can be geographically unbalanced. Chinese clinical data may help evaluate effectiveness, adverse effects, dosing, adherence, and treatment patterns in a population that is not always adequately represented in global trials.
For patients, evidence synthesis does not mean that one antipsychotic is automatically right for everyone. Treatment choice depends on the diagnosis, current symptoms, previous response, side effects, metabolic risk, movement symptoms, sleep, pregnancy plans, liver and kidney function, and the patient's preferences.
Patients should not stop an antipsychotic suddenly without medical guidance. A safe treatment plan may include gradual dose changes, metabolic monitoring, movement-disorder assessment, psychotherapy, family education, and crisis planning.
Our Psychiatry at Huashan Hospital Shanghai article and the Shanghai Mental Health Center psychiatry guide provide related background.
Clinical profile: A psychopharmacology program connecting Chinese clinical evidence with international comparative effectiveness research.
4. How to Interpret These Mental-Health Innovations
The three programs represent different forms of progress:
- Screening and prevention: accessible cognitive tools designed to identify people who may need a fuller assessment.
- Emerging intervention: glymphatic-system procedures and closed-loop BCI that remain dependent on clinical evidence and specialist monitoring.
- Evidence improvement: international review of antipsychotic effectiveness using Chinese real-world and database evidence.
Mental-health and cognitive innovations require careful communication because labels such as “early screening,” “brain stimulation,” or “precision psychiatry” can sound more definitive than the underlying evidence. Patients and families should ask what outcome improved, how long it lasted, how it was measured, and whether the intervention is available outside a research setting.
5. How CMCS Helps International Patients Communicate with Mental-Health Specialists
For an international patient or family seeking psychiatric, cognitive, or neurotechnology care in Shanghai, the first step is to match the clinical question with the right specialist team. China Medical Concierge Shanghai (CMCS) is a health management and medical coordination service that helps patients connect with specialist doctors and hospital resources in Shanghai. CMCS is not a hospital and does not independently diagnose or prescribe treatment.
Before a consultation, CMCS can help organize cognitive assessments, brain imaging, sleep studies, laboratory tests, genetic or biomarker results, psychiatric records, medication history, psychotherapy records, stimulation or rehabilitation records, school or work observations, and current symptoms. For overseas patients, these records can be arranged into a concise English medical summary for the specialist.
CMCS can help patients and families prepare focused questions such as:
- Is the proposed screening tool diagnostic, or does it only identify people who need a full assessment?
- Is the glymphatic intervention or BCI treatment approved, available through an investigator-initiated trial, or still experimental?
- What diagnosis and eligibility criteria are required, and what alternative treatments should be considered?
- What are the risks involving mood worsening, sleep, seizures, cognition, medication interactions, infection, or device use?
- How will benefit be measured, and how long should improvement be expected to last?
- What crisis plan, family support, follow-up, and emergency contact system will be available?
During the consultation, CMCS can assist with appointment coordination, medical interpretation, communication between the patient or family and the care team, and clarification of the doctor's recommendations. Afterward, a case manager can help organize the proposed next steps, identify additional tests or records, clarify the follow-up schedule, and coordinate further communication with the hospital.
The final treatment decision must be made by the patient, family where appropriate, and the treating medical team. CMCS does not independently select a psychiatric medicine, BCI program, cognitive intervention, or clinical trial. Its role is to help the patient bring complete information to the right specialist and ensure that evidence, eligibility, risks, alternatives, access, and monitoring are discussed clearly.
To learn more about mental-health and specialist consultations in Shanghai, contact CMCS:
Email: contract@medicalsh.com
WhatsApp: Contact CMCS on WhatsApp
Website: medicalsh.com
Conclusion
The Shanghai Mental Health Center teams reviewed here are advancing mental-health care through accessible cognitive screening, glymphatic-system research, non-invasive closed-loop BCI, and international evidence evaluation of antipsychotic medicines.
For patients and families, the goal is not to pursue every new brain technology, but to identify the option that fits the diagnosis, age, symptoms, previous treatment, risk profile, and personal goals. This article was prepared from the team and program information provided for editorial use. Research findings, treatment claims, product status, and clinical availability should be confirmed through the hospital, research team, regulatory authorities, and formally published studies. This article is for medical education only and is not individualized medical advice.
0 Kommentare